AZ’s Calquence Hits Endpoint In Second CLL Phase III Study

 
• By Scrip Team

The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.

Cycling
Calquence in pursuit of Imbruvica • Source: Shutterstock

More from Clinical Trials

More from R&D